Nordicus Partners Corp (NORD) stock
Close on Nov 16, 2026Market cap $55.80MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $55.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$5.07M
- EPS, diluted
- -$0.28
- Free cash flow
- -$4.34M
- Book value per share
- $3.21
- Diluted shares
- 19M
Trading
- Previous close
- $2.51
- Open
- $2.44
- Day's range
- $2.29 – $3.10
- Volume
- 27,646
- Average volume (20 days)
- 16,045
- 52-week range
- $1.48 – $5.15
- RSI (14 days)
- 40.9
- Volatility (1 year)
- 208.3%
- Relative volume
- 4.44×
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | NORD | S&P 500 | Difference | NORD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -29.0% | -3.1% | −25.9 pts | ||
| 3 months | +6.3% | -4.5% | +10.7 pts | ||
| Year to date | -42.6% | +9.4% | −52.0 pts | ||
| 1 year | -41.4% | +11.3% | −52.7 pts | ||
| 3 years | -64.1% | +70.4% | −134.5 pts | -28.9% | +19.4% |
| 5 years | -80.9% | +68.6% | −149.5 pts | -28.2% | +11.0% |
| 10 years | -87.9% | +297.7% | −385.6 pts | -19.0% | +14.8% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nordicus Partners filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Update
- Update
- Update
About Nordicus Partners
Services-Management Consulting Services
Nordicus Partners Corporation is a biotechnology firm that acquires and develops early-stage drug candidates focusing on inflammation and immune modulation. Its portfolio includes three preclinical research subsidiaries developing treatments for patients with oral disorders and inflammatory skin conditions. Orocidin A/S develops QR-01, an oral formulation for aggressive periodontitis. Bio-Convert A/S develops QR-02, a mucoadhesive oral gel for oral leukoplakia lesions. NoviThera ApS develops QR-04, a monoclonal antibody treatment for psoriasis. In addition, the firm holds a minority interest in a commercial real estate mortgage banking business.
Company profile, executives and historyNordicus Partners stock: common questions
What is Nordicus Partners's stock price?
NORD closed at $2.87 on Nov 16, 2026, up 14.34% on the day. Over the past 52 weeks it traded between $1.48 and $5.15.
What is Nordicus Partners's market cap?
Nordicus Partners was worth $55.80M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is NORD's P/E ratio?
Nordicus Partners lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.28), so it has no meaningful P/E ratio.
Does Nordicus Partners pay a dividend?
No. Nordicus Partners has not paid a cash dividend over the last twelve months.
How has NORD stock performed over the past year?
Including dividends, NORD returned -41.4% over the past year, against +11.3% for the S&P 500.
How many NORD shares are sold short?
0M shares were sold short at the latest FINRA report, 0.07% of the float, or 1.0 days of average trading volume.
Who are Nordicus Partners's competitors?
Companies most similar to Nordicus Partners by business, industry and size include BLNC, LEEN, GFLT, HSTA, BDTB.
See a number that looks wrong?